-transparent.png){kind=logo}
The kininogenase, tissue kallikrein (EC 3.4.21.8), has been identified in different blood vessels. The enzyme was mainly found in vascular smooth muscle cells. It is not known whether it is present and functionally active in vascular endothelial cells. The following study investigates the presence of tissue kallikrein in endothelial cells from human umbilical veins and pulmonary arteries. Tissue kallikrein was demonstrated in three ways: 1) by immunostaining in endothelial cells; 2) by measurement of tissue kallikrein activity using a colorimetric assay; 3) by the measurement of kinin release in intact and homogenised endothelial cells with a radioimmunoassay. Immunostaining demonstrated the presence of tissue kallikrein in endothelial cells from human umbilical veins and endothelial cells from human pulmonary arteries. Tissue kallikrein-like activity, measured by the degradation of D-Val-cyclohexyl-Ala-Arg-4-nitraniline, was 3.57 +/- 0.5 mU/10(6) endothelial cells from human umbilical veins and 7.52 +/- 0.84 mU/10(6) endothelial cells from human pulmonary arteries. Intracellular kinin concentrations were 424 +/- 83 pg/10(6) cells in endothelial cells from human umbilical veins and 576 +/- 146 pg/10(6) cells in endothelial cells from human pulmonary arteries, and they increased in a time-dependent manner after homogenisation. The increase was abolished by aprotinin (1000 kIU), an inhibitor of tissue kallikrein in both cell types. Addition of exogenous kallikrein (5 mU) to homogenised cells led to a five fold increase of kinin concentrations after five minutes, indicating a sufficient resource of cellular kininogen. Removal of extracellularly bound kininogen by washing with dextran sulphate (100 mg/l) resulted in an approximately 75% reduction of the cellular kinin release.(ABSTRACT TRUNCATED AT 250 WORDS)
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
November 2000,
Biological chemistry,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
January 1979,
Advances in experimental medicine and biology,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
January 1986,
Biomedica biochimica acta,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
January 1999,
Proceedings of the Association of American Physicians,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
January 1992,
Agents and actions. Supplements,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
February 2003,
Biochimica et biophysica acta,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
May 2004,
Biochimica et biophysica acta,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
October 1977,
Biochemical pharmacology,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
January 2014,
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,
K Graf, and
M Gräfe, and
W Auch-Schwelk, and
C R Baumgarten, and
H Scheffer, and
A Hildebrandt, and
E Fleck
January 1986,
Advances in experimental medicine and biology,
